Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,435 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of Family Status of Osteopathic Medical Students on Their Perceived Level of Stress.

NCT06042504
View directory record Official record
Conditions
Stress, Psychological
Interventions
Survey
Other
Lead sponsor
The Touro College and University System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Not applicable Interventional

CPR Audiovisual Tool to Impact ICU Patients' Surrogate Anxiety Level.

NCT03630965
View directory record Official record
Conditions
Critical Illness
Interventions
CPR Video
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 26, 2026, 2:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

NCT00974064
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Chronic Bronchitis, Emphysema
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

NCT04580121
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Professional Coaching on Early Career Academic Emergency Physicians

NCT03125330
View directory record Official record
Conditions
Development, Human, Well-Being, Professional Burnout, Goals, Leadership, Professional Role, Physician's Role, Stress, Anxiety
Interventions
Professional coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 26, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

NCT00011011
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 26, 2026, 2:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
revumenib, cobicistat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
30 Days and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

NCT02680184
View directory record Official record
Conditions
Melanoma
Interventions
CMP-001, Pembrolizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Changing Health and Lifestyle Behaviors of Offspring Following Maternal Bariatric Surgery

NCT05350267
View directory record Official record
Conditions
Obesity, Childhood
Interventions
HALO, Enhanced Standard of Care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 26, 2026, 2:45 PM EDT
Withdrawn Not applicable Interventional

A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs

NCT00037063
View directory record Official record
Conditions
HIV Infections
Interventions
Thiamine hydrochloride, Riboflavin, Ascorbic acid, Vitamin E
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Denver, Colorado • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 26, 2026, 2:45 PM EDT
Active, not recruiting Phase 1 Interventional

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

HMPL-A830 in Solid Tumors

NCT07718581
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HMPL-A830
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Orange, California • Coral Springs, Florida • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

NCT01910571
View directory record Official record
Conditions
Healthy
Interventions
P7435, Placebo
Drug · Other
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 26, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681
View directory record Official record
Conditions
Solid Tumors, Advanced Solid Tumor
Interventions
BG-C0902
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of the Face and Neck With Lower Ulthera System Energy Settings

NCT01713998
View directory record Official record
Conditions
Skin Laxity
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 26, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional

PET/CT Characterization of Treatment Resistance

NCT05647564
View directory record Official record
Conditions
Prostate Cancer
Interventions
F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET)
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 2:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

NCT04680026
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
HBI-3000, Placebo
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 26, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 26, 2026, 2:45 PM EDT
Terminated Phase 1 Interventional

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868
View directory record Official record
Conditions
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Interventions
MYTX-011
Drug
Lead sponsor
Mythic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 26, 2026, 2:45 PM EDT
Terminated Phase 1 Interventional

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions
PF-06940434, PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 26, 2026, 2:45 PM EDT
Terminated Not applicable Interventional

Reducing Readmissions in High-Risk Ostomates

NCT02658123
View directory record Official record
Conditions
Ileostomy
Interventions
Pre-operative education (standard of care), Home health care visits (standard of care), Follow-up post-operative visits, Patient Data Collection Form, Healthcare Utilization Form, The City of Hope QOL Survey for Ostomy Patients, Phone call with CWOCN or PA
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 26, 2026, 2:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

NCT01125293
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Everolimus, Rituximab, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 26, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Results available

The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma

NCT01235793
View directory record Official record
Conditions
B-Cell Lymphoma Originating in the CNS
Interventions
Temozolomide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 26, 2026, 2:45 PM EDT